Cargando…

Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway

SUMMARY: Glucocorticoid use is a risk factor for osteoporosis and fractures. We studied whether women initiating glucocorticoid treatment also started anti-osteoporotic treatment, according to clinical guidelines. Women with versus without previous fracture were twice as likely to start anti-osteopo...

Descripción completa

Detalles Bibliográficos
Autores principales: Apalset, Ellen M., Lunde, Astrid, Hoff, Mari, Ehrenstein, Vera, Tell, Grethe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406535/
https://www.ncbi.nlm.nih.gov/pubmed/32757143
http://dx.doi.org/10.1007/s11657-020-00783-8
_version_ 1783567444298694656
author Apalset, Ellen M.
Lunde, Astrid
Hoff, Mari
Ehrenstein, Vera
Tell, Grethe S.
author_facet Apalset, Ellen M.
Lunde, Astrid
Hoff, Mari
Ehrenstein, Vera
Tell, Grethe S.
author_sort Apalset, Ellen M.
collection PubMed
description SUMMARY: Glucocorticoid use is a risk factor for osteoporosis and fractures. We studied whether women initiating glucocorticoid treatment also started anti-osteoporotic treatment, according to clinical guidelines. Women with versus without previous fracture were twice as likely to start anti-osteoporotic treatment within 1 year after initiating glucocorticoid treatment, but the cumulative incidences were low 9.1% vs. 4.6%, respectively. PURPOSE: Use of glucocorticoids (GC) is a risk factor for osteoporosis and fractures, and clinical guidelines suggest that preventive treatment with anti-osteoporotic drugs (AOD) should be considered when starting GC. Women with high risk of osteoporosis comprise those with previous fractures or a known inflammatory rheumatic disease, for whom the indication of AOD is even stronger. The purpose of these analyses was to investigate whether women initiating GC treatment also started AOD, especially those with high risk of osteoporosis. METHODS: We used data from the Norwegian Prescription Database to identify all women 55 years and older initiating GC treatment in Norway during 2010–2016 and to obtain information on use of AOD. Data from the Norwegian Patient Registry were used to obtain information on previous fractures and diagnoses. RESULTS: Among 105,477 women initiating GC treatment during 2010–2016, 3256 had started AOD and 79,638 had discontinued GC treatment after 1-year follow-up. Cumulative incidence of starting AOD after 1 year was 9.1% (95% CI: 7.9, 10.4) for women with vs. 4.6% (95% CI: 4.4%, 4.8%) for women without a previous fracture. Women with rheumatoid arthritis or another inflammatory rheumatic disease were more likely to start AOD than women with other indications. For the whole cohort, the probability of starting AOD treatment within 1 year after initiating GC increased on average 3% per year (HR = 1.03, CI: 1.01, 1.05) from 2010 to 2016. CONCLUSIONS: Having had a previous fracture or an inflammatory rheumatic disease increased the probability of treatment with AOD. However, the proportions starting AOD were much lower than clinically indicated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-020-00783-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7406535
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-74065352020-08-13 Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway Apalset, Ellen M. Lunde, Astrid Hoff, Mari Ehrenstein, Vera Tell, Grethe S. Arch Osteoporos Original Article SUMMARY: Glucocorticoid use is a risk factor for osteoporosis and fractures. We studied whether women initiating glucocorticoid treatment also started anti-osteoporotic treatment, according to clinical guidelines. Women with versus without previous fracture were twice as likely to start anti-osteoporotic treatment within 1 year after initiating glucocorticoid treatment, but the cumulative incidences were low 9.1% vs. 4.6%, respectively. PURPOSE: Use of glucocorticoids (GC) is a risk factor for osteoporosis and fractures, and clinical guidelines suggest that preventive treatment with anti-osteoporotic drugs (AOD) should be considered when starting GC. Women with high risk of osteoporosis comprise those with previous fractures or a known inflammatory rheumatic disease, for whom the indication of AOD is even stronger. The purpose of these analyses was to investigate whether women initiating GC treatment also started AOD, especially those with high risk of osteoporosis. METHODS: We used data from the Norwegian Prescription Database to identify all women 55 years and older initiating GC treatment in Norway during 2010–2016 and to obtain information on use of AOD. Data from the Norwegian Patient Registry were used to obtain information on previous fractures and diagnoses. RESULTS: Among 105,477 women initiating GC treatment during 2010–2016, 3256 had started AOD and 79,638 had discontinued GC treatment after 1-year follow-up. Cumulative incidence of starting AOD after 1 year was 9.1% (95% CI: 7.9, 10.4) for women with vs. 4.6% (95% CI: 4.4%, 4.8%) for women without a previous fracture. Women with rheumatoid arthritis or another inflammatory rheumatic disease were more likely to start AOD than women with other indications. For the whole cohort, the probability of starting AOD treatment within 1 year after initiating GC increased on average 3% per year (HR = 1.03, CI: 1.01, 1.05) from 2010 to 2016. CONCLUSIONS: Having had a previous fracture or an inflammatory rheumatic disease increased the probability of treatment with AOD. However, the proportions starting AOD were much lower than clinically indicated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-020-00783-8) contains supplementary material, which is available to authorized users. Springer London 2020-08-05 2020 /pmc/articles/PMC7406535/ /pubmed/32757143 http://dx.doi.org/10.1007/s11657-020-00783-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Apalset, Ellen M.
Lunde, Astrid
Hoff, Mari
Ehrenstein, Vera
Tell, Grethe S.
Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title_full Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title_fullStr Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title_full_unstemmed Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title_short Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
title_sort initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in norway
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406535/
https://www.ncbi.nlm.nih.gov/pubmed/32757143
http://dx.doi.org/10.1007/s11657-020-00783-8
work_keys_str_mv AT apalsetellenm initiationofantiosteoporoticdrugsinhighriskfemalepatientsstartingglucocorticoidtreatmentapopulationstudyinnorway
AT lundeastrid initiationofantiosteoporoticdrugsinhighriskfemalepatientsstartingglucocorticoidtreatmentapopulationstudyinnorway
AT hoffmari initiationofantiosteoporoticdrugsinhighriskfemalepatientsstartingglucocorticoidtreatmentapopulationstudyinnorway
AT ehrensteinvera initiationofantiosteoporoticdrugsinhighriskfemalepatientsstartingglucocorticoidtreatmentapopulationstudyinnorway
AT tellgrethes initiationofantiosteoporoticdrugsinhighriskfemalepatientsstartingglucocorticoidtreatmentapopulationstudyinnorway